Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Leap Therapeutics Inc. LPTX

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:LPTX)

Fundamentals Snapshot (NDAQ:LPTX)

Bullboard Posts (NDAQ:LPTX)

4 SMALL-CAP BIOTECH STOCKS FOR YOUR INVESTMENT PORTFOLIO!

$LPTX $VYGR $OCUL $MNMD   Clinical-Stage companies offer an exciting investment opportunity with massive upside potential....
AviseAnalytics - November 1, 2021

still holding this stock

breaking out to the upside,so glta shareholders.
coolfooldumbguy - February 19, 2020

still holding this stock

from last spring and it looks like an upswing is in progress after all this time,so glta shareholders.
coolfooldumbguy - January 23, 2020

In

@ 1.90
puffdragon699 - March 28, 2019

it's a buy today for me

this morning,it should do well in the biotech work it is doing,so glta.
coolfooldumbguy - March 18, 2019